3Fabbro-Perap P,Sotto A,Defez C,et al.Mortality attributable to healthcare-associated infections a cohort of patients with and without healthcare-associated infection in a French university hospital[J].J Control Hosp Epidemiol,2007(28):265-272.
4Kurutkan MN,Kara O,Eraslan IH.An implementation on the social cost of hospital acquired infections[J].Int J Clin Exp Med,2015,8(3):4433-4445.
5Stefkovicova M,Rovny I,Brnova J.Point prevalence survey of healthcare-associated infections in Slovakia:from zero to real data[J].Antimicrob Resist Infect Contr,2015,4(1):277.
6Kumara A,Biswalb M,Dhaliwala N,et al.Point prevalence surveys of healthcare-associated infections and use of indwelling devices and antimicrobials over three years in a tertiary care hospital in India[J].J Hosp Infect,2014,86(4):272-274.
7Sultan A,Rizvi M,Khan F,et al.Increasing antimicrobial resistance among uropathogens:is fosfomycin the answer?[J].Urol Ann,2015,7(1):26-30.
8Cornejo-Juareza P,Vilar-Comptea D,Perez-Jimeneza C,et al.The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit[J].Int J Infect Dis,2015(31):31-34.
9Dettori M,Piana A,Deriu MG,et al.Outbreak of multidrugresistant Acinetobacter baumannii in an intensive care unit[J].New Microbiologica,2014,37(2):185-191.
10El-Ageery SM,Abo-Shadi MA,Alghaithy AA,et al.Epidemiological investigation of nosocomial infection with multidrug-resistant Acinetobacter baumannii[J].Eur Rev Med Pharmacol Sci,2012,16(13):1834-1839.
